Rein Therapeutics, Inc. RNTX
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
-66.28
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $0 | -$49.9M | — | — | $16.9M |
| 2024 | $0 | -$62.9M | — | — | $54.4M |
| 2023 | $0 | -$15.7M | — | — | $98.3M |
| 2022 | $0 | -$27.3M | — | — | $18.6M |
| 2021 | $0 | -$26.2M | — | -$23.9M | $43.9M |
| 2020 | $0 | -$27.3M | — | -$20.5M | $12.2M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| VON RICKENBACH JOSEF H | director | 2026-05-27 | Buy | 4,500 | $1.07 |
| VON RICKENBACH JOSEF H | director | 2026-05-26 | Buy | 23,190 | $1.06 |
| VON RICKENBACH JOSEF H | director | 2026-05-22 | Buy | 15,950 | $1.05 |
| VON RICKENBACH JOSEF H | director | 2026-05-21 | Buy | 3,420 | $1.04 |
| WINDSOR JAMES BRIAN | See Remarks | 2026-04-30 | Buy | 25,000 | $1.00 |
| Voss Capital, LP | 10% owner | 2025-11-14 | Buy | 104,183 | $1.22 |
| Voss Capital, LP | 10% owner | 2025-10-28 | Buy | 178,392 | $1.39 |
| Voss Capital, LP | 10% owner | 2025-10-27 | Buy | 92,642 | $1.37 |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -66.28 (distress)
- Working capital / assets -0.077
- Retained earnings / assets -16.61
- EBIT / assets -2.096
- Equity / liabilities 2.337
Source: SEC EDGAR filings · CIK 0001420565 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.